Wuxi Biologics (Cayman) (2269) AI Stock Analysis

• Market Cap: HK$146.63B
• Dividend Yield: N/A
• Average Volume (3M): 32.67M
• Price to Earnings (P/E): 10.6
• Beta (1Y): 1.69
• Revenue Growth: 16.90%
• EPS Growth: 63.11%
• Country: HK
• Employees: 12,575
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.62
• Shares Outstanding: 4,137,541,000
• 10 Day Avg. Volume: 33,789,006
• 30 Day Avg. Volume: 32,668,415
• PEG Ratio: 0.00
• Price to Book (P/B): 1.61
• Price to Sales (P/S): 3.60
• P/FCF Ratio: 52.28
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$49.78
• Price Target Upside: 30.03% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): 1.29
• Revenue Forecast (FY): HK$25.52B

• Rating: 63 Neutral
• Price Target: HK$39.00 ▲(1.88% Upside)
• Action: Downgraded Date: 11/18/25
• Date: Action: Downgraded 11/18/25

Wuxi Biologics' strong financial performance is a significant positive factor, showcasing robust growth and a stable financial position. However, technical analysis indicates bearish momentum, and the valuation suggests the stock may be overvalued. The lack of earnings call data and corporate events limits additional insights.

Positive Factors

Revenue Growth

Sustained >20% CAGR across 2019–2024 indicates durable demand for Wuxi's CDMO services and expanding client adoption. Long-term growth supports higher capacity utilization, recurring service revenue, and justifies continued capital investment in facilities and tech to capture future biologics demand.

Margin Sustainability

Consistently strong gross and net margins reflect pricing power, scalable operations and effective cost controls in biologics manufacturing. High margins provide a durable buffer against input cost swings, enable reinvestment in R&D and capacity, and underpin long-term free cash generation potential.

Conservative Capital Structure

Very low leverage and a high equity ratio give the company financial flexibility to fund capex and take on long-term client projects without aggressive refinancing needs. This conservative balance sheet lowers bankruptcy risk and supports strategic investments and partnership opportunities over the medium term.

Negative Factors

Free Cash Flow Variability

Volatile FCF history despite recent improvement means cash generation is sensitive to timing of contracts and capex cycles. That variability can constrain organic funding for large-scale capacity additions, making the company more reliant on external financing or equity to finance sustained growth.

Rising Liabilities

A gradual rise in liabilities, even from a low base, can signal growing short-term funding needs or higher working capital requirements as business scales. Over time this could pressure liquidity metrics or require additional financing, reducing the margin of safety provided by the previously conservative capital structure.

Concentration on CDMO Model

Heavy dependence on the CDMO model exposes Wuxi to industry cyclicality, client concentration, and competitive pricing pressure. While long-term contracts mitigate some risk, losing a few big clients or shifts in biotech outsourcing strategies could materially impact revenue visibility and utilization rates over the medium term.

Wuxi Biologics (Cayman) Business Overview & Revenue Model

Company Description

WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.

How the Company Makes Money

Wuxi Biologics generates revenue primarily through its contract development and manufacturing organization (CDMO) services, which include process development, clinical and commercial manufacturing of biologics. The company typically enters into long-term contracts with clients, providing steady revenue streams from service fees and milestone payments. Key revenue streams also include upfront fees for services, royalties from product sales, and income from collaborations and partnerships with pharmaceutical firms. Significant partnerships with major pharmaceutical companies and biotech firms further bolster its earnings, as these collaborations often lead to increased demand for its services and shared revenue opportunities.

Wuxi Biologics (Cayman) Financial Statement Overview

Summary

Wuxi Biologics demonstrates strong financial health with robust revenue and profit growth, efficient cost management, and a stable capital structure. The low leverage and solid cash flow management further enhance its financial position. Potential risks include fluctuations in free cash flow and a gradual increase in liabilities.

Income Statement

Wuxi Biologics has demonstrated strong revenue growth with a compound annual growth rate of over 20% from 2019 to 2024. The gross profit margin consistently exceeds 40%, indicating efficient cost management. The net profit margin has remained stable around 18% to 20%, showcasing solid profitability. EBIT and EBITDA margins are healthy, reflecting strong operational performance. Overall, the income statement highlights robust growth and profitability with minimal weaknesses.

Balance Sheet

The balance sheet of Wuxi Biologics is solid with a low debt-to-equity ratio of approximately 0.12, indicating conservative leverage. The equity ratio is strong, consistently above 70%, suggesting a stable capital structure. Return on equity is impressive, consistently above 8%, reflecting efficient use of shareholders' funds. However, the slight increase in total liabilities over time could be monitored for potential risk.

Cash Flow

Cash flow statements reveal positive trends with free cash flow turning positive in 2024 after previous years of negative figures. Operating cash flow has increased steadily, showing robust cash generation from operations. The free cash flow to net income ratio improved significantly, indicating enhanced cash efficiency. However, the variability in free cash flow over the years suggests some fluctuations in capital expenditures.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	20.05B	18.68B	17.03B	15.27B	10.29B	5.61B
Gross Profit	8.55B	7.65B	6.83B	6.72B	4.83B	2.53B
EBITDA	7.41B	6.43B	5.50B	6.22B	4.51B	2.31B
Net Income	4.20B	3.36B	3.40B	4.42B	3.39B	1.69B
Balance Sheet
Total Assets	60.44B	56.98B	56.58B	49.56B	44.03B	28.96B
Cash, Cash Equivalents and Short-Term Investments	12.54B	10.71B	11.24B	8.71B	11.13B	8.48B
Total Debt	5.11B	4.94B	4.56B	4.42B	4.30B	3.33B
Total Liabilities	11.37B	11.50B	12.56B	13.35B	11.33B	8.06B
Stockholders Equity	44.95B	41.82B	40.33B	35.05B	32.28B	20.56B
Cash Flow
Free Cash Flow	1.76B	1.29B	437.20M	-326.72M	-3.09B	-4.14B
Operating Cash Flow	5.72B	5.22B	4.67B	5.54B	3.43B	1.88B
Investing Cash Flow	-4.10B	-3.94B	-3.23B	-5.91B	-9.60B	-7.22B
Financing Cash Flow	-2.36B	-2.75B	1.96B	-2.59B	8.21B	6.57B

Wuxi Biologics (Cayman) Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 38.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2269, the sentiment is Negative. The current price of 38.28 is below the 20-day moving average (MA) of 38.96, above the 50-day MA of 37.28, and above the 200-day MA of 33.08, indicating a neutral trend. The MACD of -0.13 indicates Positive momentum. The RSI at 39.72 is Neutral, neither overbought nor oversold. The STOCH value of 6.60 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2269.

Wuxi Biologics (Cayman) Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1530	68 Neutral	HK$50.10B	9.63	15.34%	0.95%	7.51%	44.09%
2269	63 Neutral	HK$146.63B	10.60	9.79%	―	16.90%	63.11%
1801	61 Neutral	$136.13B	36.49	8.41%	―	52.78%	―
1177	54 Neutral	$105.70B	12.76	11.72%	1.40%	13.69%	50.71%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
9926	45 Neutral	HK$93.96B	-32.76	-14.40%	―	33.46%	-7.60%
1877	38 Underperform	HK$30.62B	-22.62	-15.06%	―	38.56%	48.26%

Wuxi Biologics (Cayman) Corporate Events

WuXi Biologics’ Substantial Shareholder to Cut Stake via HK$38.52 Block Trade

WuXi Biologics announced that substantial shareholder WuXi Biologics Holdings Limited has agreed to sell 150 million existing shares, or about 3.63% of the company’s issued share capital, via a block trade arranged by Morgan Stanley at HK$38.52 per share to independent investors. Following completion, WuXi Biologics Holdings’ stake will fall from roughly 12.12% to 8.49%, meaning it will no longer qualify as a substantial shareholder, while it has also agreed to a 90-day lock-up on further disposals, a move that reshapes the company’s shareholding structure and may influence investor perceptions of control and future share liquidity.

The most recent analyst rating on (HK:2269) stock is a Buy with a HK$37.36 price target. To see the full list of analyst forecasts on Wuxi Biologics (Cayman) stock, see the HK:2269 Stock Forecast page.

Citigroup-Backed HK$4.00 Cash Offer Launched for Wuxi Biologics Shares at 99% Premium

Citigroup Global Markets Asia will, on behalf of an unnamed offeror, launch a voluntary conditional cash offer for all issued shares of Wuxi Biologics (Cayman) not already owned by the offeror and its concert parties, as well as a related offer to cancel all outstanding share options. The offer is priced at HK$4.00 per share, representing a 99% premium to the company’s last undisturbed closing price of HK$2.01, and is structured as a cash-only proposal that will not be increased, signaling a substantial potential change in ownership and control that could constitute a major transaction for the offeror and a discloseable transaction for Wuxi Biologics, with implications for existing shareholders and the trading of its Hong Kong–listed shares.

The most recent analyst rating on (HK:2269) stock is a Buy with a HK$37.36 price target. To see the full list of analyst forecasts on Wuxi Biologics (Cayman) stock, see the HK:2269 Stock Forecast page.

WuXi Biologics Highlights Strong 2025 Pipeline and Growth Ahead of J.P. Morgan Healthcare Conference

WuXi Biologics announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference on 14 January 2026, using the forum to share detailed information on its business operations and recent performance with global investors. The company reported strong operational and financial momentum in 2025, adding 209 new projects to reach a total of 945, including 74 phase III and 25 commercial manufacturing programs, and achieving record upfront and total payments on its research platform with new contracts carrying potential milestones exceeding USD4 billion. With roughly two-thirds of new projects centered on bispecifics, multispecifics and ADCs, and a solid execution record in process performance qualification—28 PPQs completed in 2025 and 34 already secured for 2026—the company signals continued growth prospects and reinforced positioning in high-value biologics outsourcing, while cautioning investors to exercise care in interpreting the disclosed information.

The most recent analyst rating on (HK:2269) stock is a Buy with a HK$37.36 price target. To see the full list of analyst forecasts on Wuxi Biologics (Cayman) stock, see the HK:2269 Stock Forecast page.